(Q34511787)

24930388

2 August 2017

title

Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer (English)

1 reference

2 August 2017

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24930388%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

7

Hope S Rugo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24930388%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

9

Denise A Yardley

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24930388%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

author name string

Peter A Kaufman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24930388%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Kenneth J Bloom

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24930388%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Howard Burris

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24930388%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Julie R Gralow

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24930388%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Musa Mayer

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24930388%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Mark Pegram

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24930388%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Miu Chau

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24930388%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Deepa Lalla

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24930388%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Bongin Yoo

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24930388%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Melissa G Brammer

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24930388%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Charles L Vogel

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24930388%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

language of work or name

English

0 references

publication date

13 June 2014

1 reference

2 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24930388%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

volume

120

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24930388%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

issue

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24930388%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

page(s)

2657-2664

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24930388%20AND%20SRC:MED&resulttype=core&format=json

Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005).

8 June 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4232097

Trastuzumab emtansine for HER2-positive advanced breast cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4232097

7 July 2018

Cancer statistics, 2012

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4232097

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4232097

Adjuvant trastuzumab in HER2-positive breast cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4232097

The Clinical Importance of the Heterogeneity of HER2 neu.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4232097

Breast cancer heterogeneity: mechanisms, proofs, and implications

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4232097

Estimating recurrences prevented from using trastuzumab in HER-2/neu-positive adjuvant breast cancer in the United States.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4232097

Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4232097

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4232097

HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4232097

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4232097

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4232097

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4232097

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4232097

Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4232097

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4232097

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4232097

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4232097

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4232097

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4232097

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

7 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FCNCR.28710

Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FCNCR.28710

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update

21 January 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4232097

27 October 2018

https://api.crossref.org/works/10.1002%2FCNCR.28710

Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies

21 January 2018

1 reference

12 December 2020

Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831

1 reference

12 December 2020

HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial

1 reference

12 December 2020

Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab

1 reference

12 December 2020

Concordance between central and local laboratory HER2 testing from a community-based clinical study

1 reference

12 December 2020

Identifiers

DOI

10.1002/CNCR.28710

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24930388%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24930388%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

24930388

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24930388%20AND%20SRC:MED&resulttype=core&format=json